Autem Therapeutics is an oncology therapeutic and bioelectric technology company which provides cancer care.
Autem Therapeutics has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Autem Therapeutics's investors include Zentynel Frontier Investments.
Autem Therapeutics is headquartered in Hanover, United States.
Autem Therapeutics is an oncology therapeutic and bioelectric technology company which provides cancer care.
Autem Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Autem Therapeutics — Funding & Investors." VCBacked, June 6, 2022, https://www.vcbacked.co/company/autem-therapeutics. Accessed September 30, 2026.
VCBacked. (2022). Autem Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/autem-therapeutics
{{cite web |title=Autem Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/autem-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated